[go: up one dir, main page]

MX2016009331A - Composiciones y metodos para tratar enfermedades oculares. - Google Patents

Composiciones y metodos para tratar enfermedades oculares.

Info

Publication number
MX2016009331A
MX2016009331A MX2016009331A MX2016009331A MX2016009331A MX 2016009331 A MX2016009331 A MX 2016009331A MX 2016009331 A MX2016009331 A MX 2016009331A MX 2016009331 A MX2016009331 A MX 2016009331A MX 2016009331 A MX2016009331 A MX 2016009331A
Authority
MX
Mexico
Prior art keywords
ocular
edema
diseases
methods
neovascularization
Prior art date
Application number
MX2016009331A
Other languages
English (en)
Inventor
Shalwitz Robert
Daly William
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Publication of MX2016009331A publication Critical patent/MX2016009331A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen los métodos para tratar enfermedades o estados de los ojos, especialmente retinopatías, edema ocular y neovascularización ocular. Los ejemplos no limitativos de estas enfermedades o estados incluyen edema macular diabético, degeneración macular relacionada con la edad (forma húmeda o seca) , neovascularización coroidea, retinopatía diabética, oclusión de la vena (central o de las ramas) de la retina, traumatismo ocular, edema inducido por cirugía, neovascularización inducida por cirugía, edema macular cistoide, isquemia ocular, uveítis y similares. Estas enfermedades o estados se caracterizan por cambios en la vasculatura ocular, sean progresivos o no progresivos, resultado de una enfermedad o estado agudo o de una enfermedad o estado crónico.
MX2016009331A 2014-01-23 2015-01-23 Composiciones y metodos para tratar enfermedades oculares. MX2016009331A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461930811P 2014-01-23 2014-01-23
PCT/US2015/012634 WO2015112831A1 (en) 2014-01-23 2015-01-23 Compositions and methods for treating ocular diseases

Publications (1)

Publication Number Publication Date
MX2016009331A true MX2016009331A (es) 2016-10-26

Family

ID=53681968

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009331A MX2016009331A (es) 2014-01-23 2015-01-23 Composiciones y metodos para tratar enfermedades oculares.

Country Status (11)

Country Link
US (1) US20160339005A1 (es)
EP (1) EP3096617A4 (es)
JP (1) JP2017503835A (es)
KR (1) KR20160108554A (es)
CN (1) CN106132201A (es)
AU (1) AU2015209264A1 (es)
CA (1) CA2937349A1 (es)
IL (1) IL246791A0 (es)
MX (1) MX2016009331A (es)
RU (1) RU2016133980A (es)
WO (1) WO2015112831A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3357911T (pt) 2006-06-26 2022-07-11 Akebia Therapeutics Inc Inibidores da prolil-hidroxilase e métodos de utilização
NO2686520T3 (es) 2011-06-06 2018-03-17
EP3007695B1 (en) 2013-06-13 2024-02-07 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
CR20160222U (es) 2013-11-15 2016-08-26 Akebia Therapeutics Inc Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
CA2974691A1 (en) 2015-01-23 2016-07-28 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
UA123308C2 (uk) 2015-04-01 2021-03-17 Екебіа Терапьютікс, Інк. Композиції і способи для лікування анемії
KR20180036580A (ko) 2016-09-30 2018-04-09 주식회사 유스바이오팜 수가용화(水加溶化)된 우르소데옥시콜산을 함유하는 염증성 피부질환 또는 중증 소양증 예방 또는 치료용 조성물
KR102252450B1 (ko) 2017-02-09 2021-05-14 주식회사 아미코젠파마 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물
US11064685B2 (en) * 2017-02-27 2021-07-20 Regeneron Pharmaceuticals, Inc. Non-human animal models of retinoschisis
KR102715397B1 (ko) * 2017-03-22 2024-10-10 아센디스 파마 에이에스 히드로겔 가교된 히알루론산 전구약물 조성물 및 방법
EP3618847B1 (en) * 2017-05-05 2021-04-07 Zealand Pharma A/S Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
US20220409606A1 (en) * 2017-06-15 2022-12-29 The Trustees Of Columbia University In The City Of New York Treatment of neurodegeneration via reprogramming metabolism by inhibiting phd
KR102050506B1 (ko) 2017-06-20 2019-11-29 한국식품연구원 망막 질환 예방, 개선, 완화 또는 치료용 조성물
WO2019213326A1 (en) * 2018-05-01 2019-11-07 Idrop, Inc. Eye drop formulation and method for sustained delivery of medicament to the retina
JP7440989B2 (ja) 2018-05-09 2024-02-29 アケビア セラピューティクス インコーポレイテッド ２－［５－（３－クロロフェニル）－３－ヒドロキシピリジン－２－カルボニル］アミノ］酢酸を調製するための方法
WO2020041382A1 (en) * 2018-08-21 2020-02-27 California Institute Of Technology Non-leaking or minimally-leaking choroidal or retinal revascularization
KR102294439B1 (ko) 2018-11-02 2021-08-27 경북대학교 산학협력단 황반변성 예방 또는 치료용 조성물
JP7280353B2 (ja) * 2018-11-02 2023-05-23 キョンブク ナショナル ユニバーシティ インダストリー－アカデミック コーオペレーション ファウンデーション 黄斑変性予防又は治療用組成物
SG11202105025VA (en) * 2018-11-14 2021-06-29 Zhuhai Qiwei Bio Tech Ltd Animal models, screening methods, and treatment methods for intraocular diseases or disorders
CN111308001B (zh) * 2018-12-11 2024-11-29 上海市第一人民医院 人黄斑新生血管性疾病的代谢标记物及其应用
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
IL294873A (en) * 2020-02-06 2022-09-01 Perfuse Therapeutics Inc Preparations for the treatment of eye diseases
JP2024516367A (ja) * 2021-04-13 2024-04-15 ユニティ バイオテクノロジー インコーポレイテッド 網膜血管症を治療する方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19650215A1 (de) * 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2007101204A1 (en) * 2006-02-27 2007-09-07 Alcon Research, Ltd. Method of treating glaucoma
PT3357911T (pt) * 2006-06-26 2022-07-11 Akebia Therapeutics Inc Inibidores da prolil-hidroxilase e métodos de utilização
WO2009035534A2 (en) * 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2012170442A1 (en) * 2011-06-06 2012-12-13 Akebia Therapeutics Inc. Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
CR20160222U (es) * 2013-11-15 2016-08-26 Akebia Therapeutics Inc Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas

Also Published As

Publication number Publication date
IL246791A0 (en) 2016-08-31
EP3096617A4 (en) 2017-09-13
KR20160108554A (ko) 2016-09-19
AU2015209264A1 (en) 2016-08-04
US20160339005A1 (en) 2016-11-24
JP2017503835A (ja) 2017-02-02
EP3096617A1 (en) 2016-11-30
WO2015112831A8 (en) 2016-09-01
CA2937349A1 (en) 2015-07-30
WO2015112831A1 (en) 2015-07-30
CN106132201A (zh) 2016-11-16
RU2016133980A (ru) 2018-03-01
RU2016133980A3 (es) 2018-10-26

Similar Documents

Publication Publication Date Title
MX2016009331A (es) Composiciones y metodos para tratar enfermedades oculares.
PH12013500577B1 (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
HK1201438A1 (en) Treatment of ocular disease
HK1258588A1 (zh) 用於治療眼科疾病的化合物和製劑
SG191334A1 (en) Use of a vegf antagonist to treat angiogenic eye disorders
WO2013166449A3 (en) Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
MX2022001433A (es) Tratamiento personalizado de enfermedades oftalmologicas.
MY185114A (en) Improved il-6 antibodies
NZ712030A (en) Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
HK1198811A1 (en) A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
MX2020012011A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
MX2013001870A (es) Formulaciones oftalmicas de escualamina.
MX2019011242A (es) Farmacos y composiciones para el tratamiento de trastornos oculares.
HK1219654A1 (zh) 用於治疗眼科疾病和病症的方法
HK1231694A1 (en) Compositions and methods for treating ocular diseases
TW201613596A (en) Ophthalmic suspension preparation
SG10202010303UA (en) Nanoliposomes for sustained delivery of tacrolimus for treatment of anterior segment eye diseases
山岸哲哉 et al. Fundus autofluorescence in polypoidal choroidal vasculopathy.
HK1189820A (en) Use of a vegf antagonist to treat angiogenic eye disorders
TR2024009657A1 (tr) Küçük bir aktif koroidal neovaskülerizasyon lezyonunun bulunduğu, yaşa bağlı maküler dejenerasyon tedavisi.